Patients Stopping Anti-Obesity Jabs Put On Weight at a Quadrupled Rate Than Those on Conventional Diets

New research suggests that people who stop using new GLP-1 drugs like Mounjaro or Wegovy can put back on reduced body mass much more quickly than those who stop traditional diet and exercise programs.

Research printed in a leading health publication shows that while obese individuals frequently drop substantial amounts of their total mass while undergoing treatment, the weight comes back at an average rate of 0.8 kg per month once they quit.

"Individuals using these medications need to be aware of the potential of fast weight regain when the medication ends," stated lead investigator Dr. Susan Jebb.

This pace of recovery means a reversion to starting weight in about 18 months.

Weighing Approaches

The research, which reviewed 37 of trials involving over 9,000 of participants, compared the outcomes of GLP-1 agonists with conventional dieting.

The team note that people who lose weight through diet and exercise usually see a slower weight regain—around 0.1 kg a month—once they finish.

Explaining the Quick Rebound

Experts suggest the way of the drugs is key to understanding the amplified regain.

GLP-1 drugs imitate a natural hormone called glucagon-like peptide-1, which controls appetite.

"Artificially providing the hormone concentrations far above than normal might result in the body to generate a reduced amount of its endogenous GLP-1, and could lessen responsiveness to its actions," explained Dr. Adam Collins, a nutrition specialist.

"Discontinuation of this medication results in appetite is uncontrolled, making overeating much more probable."

An Ongoing Issue?

Health authorities suggest the injections for individuals with weight-linked medical conditions, accompanied by recommended lifestyle changes.

Many experts contend that, given the high risk of weight regain, the treatment is often long-term.

This opinion is supported by pharmaceutical companies, who note that the results "highlight the persistent character of obesity," similar to managing diseases like diabetes.

Patient Experiences

People who have come off the jabs report a intense return of appetite.

"I experienced something that goes on and I was suddenly ravenous," recalled an individual.

This difficulty is worsened if users have not developed permanent lifestyle or habit changes during therapy.

Significant Use

Survey data indicate that millions of adults in the UK have tried weight-loss jabs in the past year, with demand being substantial.

• Use is more common among women compared to males.
• The 40s and 50s demographic shows the highest level of interest.
• A large proportion access the medications through private prescriptions rather than public health services.

Finally, clinicians emphasize that while these medications are powerful agents for shedding pounds, they are not a permanent cure and lasting health benefits likely depends on combined lifestyle changes.